| abstract |
FIELD: organic chemistry, medicine, virology. SUBSTANCE: invention relates to nucleoside analogs of 1,3-oxathiolanes and their using for treatment of patients with viral infections, in part, HIV-infection and hepatitis B. Invention relates to (-)-4- -amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolane-5-yl)-(1H)- -pyrimidine-2-one (I) and its pharmaceutically acceptable derivatives and a pharmaceutical composition containing their. Invention describes a new mixture consisting of (-)-4-amino- -5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolane-5-yl)-(1H)- -pyrimidine-2-one and (+)-4-amino-5-fluoro-1-(2-hydroxymethyl)- -1,3-oxathiolane-5-yl)-(1H)-pyrimidine-2-one or their pharmaceutically acceptable derivatives where (+)-enantiomer presents at amount 5 wt.-%, not above. Method of synthesis of compound (I) involves an isolation of (-)-enantiomer from a mixture of (-)- and (+)-enantiomer. Method of treatment involves administration of compound (∓). at effective dose. EFFECT: improved method of synthesis, enhanced effectiveness of compound. 24 cl, 3 tbl, 3 ex |